2017年,首款进口BTK抑制剂伊布替尼在国内获批上市,开启了B细胞淋巴瘤的靶向治疗时代,也改变了慢性淋巴细胞白血病(CLL,或简称“慢淋”)的治疗格局。 《每日经济新闻》记者注意到,2024年之前,国内只有2款BTK(布鲁顿氏酪氨酸激酶)产品获批CLL一线疗法。但今年以来,阿斯利康、诺诚健华各有一款BTK抑制剂在国内获批该适应证。而且,国内获批的4款同一适应证产品中,有3款为第二代BTK抑制剂...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.